HCPLive
IAS 2013

IAS 2013 | IAS 2013

The 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) is “the world’s biggest science focused conference on HIV and AIDS. Held every two years, the conference attracts about 6,000 delegates from all over the world and is a unique opportunity for science, health, and development journalists to access the world’s leading scientists, clinicians, public health experts and community leaders.”

Conference Coverages

Benefits of Early Initiation of Treatment in HIV-infected Individuals
Benefits of Early Initiation of Treatment in HIV-infected Individuals
Study results support early treatment, even in patients with a high CD4 count.
Developments in HIV Vaccine, Hepatitis C Care Expand Options for Co-Infected Patients, But Access Remains Limited
Researchers discussed new HIV vaccine developments in protecting antibodies capable of neutralizing many different strains of the virus and reviewed the comorbidity of HIV and hepatitis C virus (HCV).
Cardiovascular Complications in HIV-Infected Individuals
HIV-infected patients face increased risk of myocardial infarction, as well as higher risk for ART-associated dyslipidemia and insulin resistance.
Late-Breaking Studies on HIV Prevention, Transmission, and Treatment
A panel of experts discuss information from late-breaking abstracts presented at IAS 2013, including information on the two patients who remain HIV-free following stem cell transplant.
Stem Cell Transplantation May Hold Promise for HIV Infection Eradication
Two male patients with prolonged HIV infection who received hematopoietic stem cell transplants still remain virus-free several consecutive weeks after their antiretroviral treatments were discontinued this spring.
New Data on Effective Treatments for Patients with HIV
Panel discussion of study results presented at IAS 2013 focusing on strategies for using antiretroviral therapy (ART) in patients with HIV who are ART-naïve or who have failed previous therapies.
Although Global Funding Levels Are Flat, Researchers Continue to Make Breakthroughs in HIV/AIDS Prevention and Treatment
A new report says a broader base of funders committed to sustained support of HIV prevention research is need to ensure continued progress in the fight to end the AIDS epidemic.
Early Clinical Results Show Pre-Exposure Prophylaxis Products Prevent HIV, But Methods Lack Worldwide Adoption
As pre-exposure prophylaxis (PrEP) remains at the forefront of HIV prevention research, clinical trial investigators provided an update on recent oral and topical PrEP efficacy studies at the second plenary session of the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013), held June 30 to July 3 in Kuala Lumpur, Malaysia.
New HIV Treatment Guidelines Call for Early Initiation of Antiretroviral Therapy
Consolidated guidelines from the World Health Organization recommend starting treatment when a patient's CD4 count falls below 500, and also recommend a new first-line ART regimen.

Most Popular

@MDMagazine

$vacMongoViewPlus$ $vAR$